Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process
Advertisement

Related Content

China Tops U.S. In Healthcare Expansion Destination But Regulatory Burdens Weigh – Survey
Public And Private Partnerships Forge Way For China As Innovative Hub - DIA China Conference
Reforms In China's Center For Drug Evaluation Designed To Boost Innovation - DIA China Conference
Chinese Government Venture Firm Funds JV To Explore Early-stage Oncology Trials
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals
Korea FDA Prepares Guidelines On Phase 0 Clinical Trials To Draw More Early-stage Trials
U.S. FDA China Country Head Chris Hickey On FDA's Mission In China: An Interview With PharmAsia News (Part 1 of 2)
Sanofi-Aventis China R&D Head Frank Jiang On Fast And Furious Adaptation In China: An Interview With PharmAsia News (Part 2 of 2)
AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
Advertisement
UsernamePublicRestriction

Register

SC077346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel